[go: up one dir, main page]

EE04434B1 - HIV proteaasi inhibiitori bisulfaatsool - Google Patents

HIV proteaasi inhibiitori bisulfaatsool

Info

Publication number
EE04434B1
EE04434B1 EEP200000798A EEP200000798A EE04434B1 EE 04434 B1 EE04434 B1 EE 04434B1 EE P200000798 A EEP200000798 A EE P200000798A EE P200000798 A EEP200000798 A EE P200000798A EE 04434 B1 EE04434 B1 EE 04434B1
Authority
EE
Estonia
Prior art keywords
protease inhibitor
hiv protease
bisulfate salt
bisulfate
salt
Prior art date
Application number
EEP200000798A
Other languages
English (en)
Inventor
Singh Janak
Pudipeddi Madhusudhan
D. Lindrud Mark
Original Assignee
Bristol-Myers Squibb Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22104737&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EE04434(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol-Myers Squibb Company filed Critical Bristol-Myers Squibb Company
Publication of EE200000798A publication Critical patent/EE200000798A/et
Publication of EE04434B1 publication Critical patent/EE04434B1/et

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/42—Radicals substituted by singly-bound nitrogen atoms having hetero atoms attached to the substituent nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyridine Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
EEP200000798A 1998-01-20 1998-12-22 HIV proteaasi inhibiitori bisulfaatsool EE04434B1 (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7196898P 1998-01-20 1998-01-20
PCT/US1998/027382 WO1999036404A1 (en) 1998-01-20 1998-12-22 Bisulfate salt of hiv protease inhibitor

Publications (2)

Publication Number Publication Date
EE200000798A EE200000798A (et) 2002-06-17
EE04434B1 true EE04434B1 (et) 2005-02-15

Family

ID=22104737

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200000798A EE04434B1 (et) 1998-01-20 1998-12-22 HIV proteaasi inhibiitori bisulfaatsool

Country Status (38)

Country Link
US (1) US6087383A (et)
EP (1) EP1056722B1 (et)
JP (2) JP4860037B2 (et)
KR (1) KR100559283B1 (et)
CN (1) CN1116282C (et)
AR (1) AR014417A1 (et)
AT (1) ATE219057T1 (et)
AU (1) AU735875B2 (et)
BG (1) BG64774B1 (et)
BR (1) BR9814736A (et)
CA (1) CA2317736C (et)
CO (1) CO4970820A1 (et)
CZ (1) CZ293507B6 (et)
DE (1) DE69806067T2 (et)
DK (1) DK1056722T3 (et)
EE (1) EE04434B1 (et)
EG (1) EG23936A (et)
ES (1) ES2178300T3 (et)
GE (1) GEP20033026B (et)
HU (1) HU227196B1 (et)
IL (2) IL137384A0 (et)
LT (1) LT4780B (et)
LV (1) LV12522B (et)
MY (1) MY114838A (et)
NO (1) NO315605B1 (et)
NZ (1) NZ504417A (et)
PE (1) PE20000185A1 (et)
PL (1) PL190744B1 (et)
PT (1) PT1056722E (et)
RO (1) RO118869B1 (et)
RU (1) RU2186070C2 (et)
SK (1) SK283975B6 (et)
TR (1) TR200001876T2 (et)
TW (1) TW531531B (et)
UA (1) UA59432C2 (et)
UY (1) UY25345A1 (et)
WO (1) WO1999036404A1 (et)
ZA (1) ZA9956B (et)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE314343T1 (de) 2000-06-30 2006-01-15 Elan Pharm Inc Verbindungen zur behandlung der alzheimerischen krankheit
EP1392645A2 (en) * 2001-05-22 2004-03-03 Elan Pharmaceuticals, Inc. Aza hydroxylated ethyl amine compounds
US7193065B2 (en) * 2001-07-13 2007-03-20 Roche Diagnostics Operations, Inc. Protease inhibitor conjugates and antibodies useful in immunoassay
US7157561B2 (en) * 2001-07-13 2007-01-02 Roche Diagnostics Operations, Inc. Methods of inhibiting transmission of a costimulatory signal of lymphocytes
AU2004206821C1 (en) * 2003-01-14 2009-10-01 Gilead Sciences, Inc. Compositions and methods for combination antiviral therapy
TW200534879A (en) * 2004-03-25 2005-11-01 Bristol Myers Squibb Co Coated tablet formulation and method
CN101565398B (zh) * 2004-05-04 2011-12-14 布里斯托尔-迈尔斯斯奎布公司 制备阿扎那韦硫酸氢盐的方法和新的形式
US20050256314A1 (en) * 2004-05-04 2005-11-17 Soojin Kim Process employing controlled crystallization in forming crystals of a pharmaceutical
US7829720B2 (en) 2004-05-04 2010-11-09 Bristol-Myers Squibb Company Process for preparing atazanavir bisulfate and novel forms
US20050288343A1 (en) * 2004-05-19 2005-12-29 Andrew Rusowicz Process of preparing substituted carbamates and intermediates thereof
TWI415635B (zh) * 2004-05-28 2013-11-21 必治妥施貴寶公司 加衣錠片調製物及製備彼之方法
CA2588466A1 (en) * 2004-12-03 2006-06-08 Merck & Co., Inc. Use of atazanavir for improving the pharmacokinetics of drugs metabolized by ugt1a1
US7642049B2 (en) * 2006-06-30 2010-01-05 Bristol-Myers Squibb Company Method for identifying HIV-1 protease inhibitors with reduced metabolic affects through detection of human resistin polymorphisms
JP5599611B2 (ja) * 2006-07-21 2014-10-01 ギリアード サイエンシーズ， インコーポレイテッド 抗ウイルスプロテアーゼインヒビター
BG66056B1 (bg) * 2006-10-05 2010-12-30 Красимир ДЕЧЕВ Метод и инсталация за производство на трисезонна добавка към дизелово гориво
JP2010529196A (ja) 2007-06-12 2010-08-26 コンサート ファーマシューティカルズ インコーポレイテッド アザペプチド誘導体
MX2009013461A (es) * 2007-06-22 2010-01-15 Bristol Myers Squibb Co Composiciones comprimidas que contienen atazanavir.
DK2170292T3 (da) * 2007-06-22 2014-04-07 Bristol Myers Squibb Holdings Ireland Atazanavirholdige sammensætninger i tabletform
EP2178511B1 (en) * 2007-06-22 2011-03-02 Bristol-Myers Squibb Company Tableted compositions containing atazanavir
CN101778625A (zh) * 2007-06-22 2010-07-14 百时美施贵宝公司 含有阿扎那韦的压片组合物
WO2009006203A1 (en) * 2007-06-29 2009-01-08 Gilead Sciences, Inc. Therapeutic compositions and the use thereof
CN103480000A (zh) * 2007-06-29 2014-01-01 吉里德科学公司 治疗用组合物和方法
EP2288593A1 (en) * 2008-05-08 2011-03-02 Ranbaxy Laboratories Limited Process for the preparation of 3,4-epoxy-2-amino-1-substituted butane derivatives and intermediate compounds thereof
US20120121722A1 (en) 2008-12-18 2012-05-17 Anup Avijit Choudhury Atazanavir formulations
EP2376452A4 (en) 2009-01-12 2012-08-29 Hetero Research Foundation NEW SULFATE POLYMORPH OF ATAZANAVIR
WO2010138338A1 (en) 2009-05-27 2010-12-02 Merck Sharp & Dohme Corp. Hiv protease inhibitors
EP2272830A1 (en) 2009-06-18 2011-01-12 Esteve Química, S.A. Preparation process of an antivirally heterocyclic azahexane derivative
WO2011027324A1 (en) 2009-09-03 2011-03-10 Ranbaxy Laboratories Limited Polymorphic forms of atazanavir sulfate
JP6122639B2 (ja) 2009-10-26 2017-04-26 メルク・シャープ・エンド・ドーム・コーポレイション インテグラーゼ阻害剤を含有する固形医薬組成物
WO2011080562A1 (en) 2009-12-29 2011-07-07 Hetero Research Foundation Novel aza-peptides containing 2,2-disubstituted cyclobutyl and/or substituted alkoxy benzyl derivatives as antivirals
PH12012501537A1 (en) 2010-01-27 2018-02-07 Viiv Healthcare Co Antiviral therapy
EP2542527A2 (en) 2010-03-01 2013-01-09 Lupin Limited Process for the preparation of atazanavir sulfate substantially free of diastereomers
US20130203759A1 (en) 2010-04-09 2013-08-08 Faranak Nikfar ATAZANAVIR SULFATE FORMULATIONS WITH IMPROVED pH EFFECT
EA201390464A1 (ru) 2010-09-28 2013-08-30 Рациофарм Гмбх Способ сухой обработки атазанавира
WO2013014633A1 (en) 2011-07-27 2013-01-31 Ranbaxy Laboratories Limited Process for preparation of atazanavir or its bisulfate salt
US8461347B2 (en) 2011-08-05 2013-06-11 Scinopharm Taiwan, Ltd. Process for preparing form A of atazanavir sulfate
US9133157B2 (en) 2011-10-26 2015-09-15 Merck Canada Inc. HIV protease inhibitors
WO2014030173A2 (en) * 2012-08-24 2014-02-27 Laurus Labs Private Limited An improved process for the preparation of atazanavir bisulfate
WO2014036690A1 (zh) * 2012-09-04 2014-03-13 上海迪赛诺化学制药有限公司 制备阿扎那韦硫酸氢盐a型结晶的方法
EP2956439B1 (en) 2013-02-12 2019-01-09 Cipla Limited Process for preparing atazanavir sulphate
CN104250225A (zh) * 2013-06-28 2014-12-31 上海威智医药科技有限公司 阿扎那韦磷酸盐及其制备和应用
CN104250224A (zh) * 2013-06-28 2014-12-31 上海威智医药科技有限公司 阿扎那韦富马酸盐及其制备和应用
CN104250223B (zh) * 2013-06-28 2017-04-12 上海威智医药科技有限公司 阿扎那韦氢溴酸盐及其制备和应用
CN105859611A (zh) * 2016-04-18 2016-08-17 上海现代制药海门有限公司 一种阿扎那韦硫酸氢盐a型结晶的制备方法
CN109251165B (zh) * 2018-10-02 2022-09-23 国药集团川抗制药有限公司 阿扎那韦达二4-氨基苯磺酸盐及其制备方法
CN111349042B (zh) * 2018-12-20 2023-07-14 陕西理工大学 一种阿扎那韦单晶及其制备方法
US12083099B2 (en) 2020-10-28 2024-09-10 Accencio LLC Methods of treating symptoms of coronavirus infection with viral protease inhibitors

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL106600A (en) * 1992-08-07 1997-09-30 Sankyo Co Peptides, pharmaceutical compositions containing the same and processes for the preparation thereof
TW409125B (en) * 1996-04-22 2000-10-21 Novartis Ag Antivirally active heterocyclic azahexane derivatives
US5849911A (en) * 1996-04-22 1998-12-15 Novartis Finance Corporation Antivirally active heterocyclic azahexane derivatives

Also Published As

Publication number Publication date
LV12522B (en) 2000-10-20
CO4970820A1 (es) 2000-11-07
CA2317736C (en) 2004-11-02
RO118869B1 (ro) 2003-12-30
NO20003692D0 (no) 2000-07-19
PL342019A1 (en) 2001-05-07
JP2002509136A (ja) 2002-03-26
UA59432C2 (uk) 2003-09-15
LV12522A (en) 2000-08-20
PT1056722E (pt) 2002-09-30
CZ293507B6 (cs) 2004-05-12
HK1033458A1 (en) 2001-08-31
BR9814736A (pt) 2000-10-24
GEP20033026B (en) 2003-07-25
HK1033667A1 (en) 2001-09-14
RU2186070C2 (ru) 2002-07-27
SK283975B6 (sk) 2004-06-08
AR014417A1 (es) 2001-02-28
EG23936A (en) 2008-01-14
LT4780B (lt) 2001-04-25
EE200000798A (et) 2002-06-17
CN1283188A (zh) 2001-02-07
WO1999036404A1 (en) 1999-07-22
DE69806067T2 (de) 2003-01-23
CN1116282C (zh) 2003-07-30
EP1056722A4 (en) 2001-01-10
HUP0101389A2 (hu) 2001-08-28
AU735875B2 (en) 2001-07-19
IL137384A0 (en) 2001-07-24
US6087383A (en) 2000-07-11
DE69806067D1 (de) 2002-07-18
NZ504417A (en) 2001-09-28
TR200001876T2 (tr) 2000-11-21
DK1056722T3 (da) 2002-09-30
AU2010199A (en) 1999-08-02
JP4860037B2 (ja) 2012-01-25
JP2009102357A (ja) 2009-05-14
ATE219057T1 (de) 2002-06-15
LT2000067A (en) 2000-11-27
IL137384A (en) 2006-08-01
SK10622000A3 (sk) 2001-02-12
MY114838A (en) 2003-01-31
BG104618A (en) 2001-02-28
HU227196B1 (en) 2010-10-28
EP1056722B1 (en) 2002-06-12
CA2317736A1 (en) 1999-07-22
KR100559283B1 (ko) 2006-03-15
HUP0101389A3 (en) 2003-07-28
UY25345A1 (es) 2000-12-29
TW531531B (en) 2003-05-11
NO20003692L (no) 2000-07-19
ES2178300T3 (es) 2002-12-16
PE20000185A1 (es) 2000-05-14
NO315605B1 (no) 2003-09-29
BG64774B1 (bg) 2006-03-31
EP1056722A1 (en) 2000-12-06
KR20010034221A (ko) 2001-04-25
CZ20002564A3 (cs) 2000-10-11
PL190744B1 (pl) 2006-01-31
ZA9956B (en) 2000-07-05

Similar Documents

Publication Publication Date Title
EE200000798A (et) HIV proteaasi inhibiitori bisulfaatsool
PT1086076E (pt) Inibidores de sulfonamida de aspartil protease
NO20012980D0 (no) Proteaseinhibitorer
ATE264339T1 (de) Serine protease inhibitoren
NO995433D0 (no) Protease-inhibitorer
AR028253A1 (es) Inhibidores de la glucogeno fosforilasa
EE200000386A (et) Aspartüülproteaasi inhibiitorite eelravimid
PT945443E (pt) Derivados de pirimidina inibidores de hiv
NO20011966L (no) Serin-protease-inhibitor
ATE223909T1 (de) Sulfamide-metalloprotease inhibitoren
NO20004696D0 (no) Kinoloner som serinproteaseinhibitorer
DK1686113T3 (da) Inhibitorer af aspartylprotease
NO995435D0 (no) Protease-inhibitorer
NO995268D0 (no) Proteaseinhibitorer
NO995434D0 (no) Proteaseinhibitorer
DE59806475D1 (de) Urokinase-inhibitoren
IT1324892B (it) Miscele di agenti stabilizzanti
IT1324893B (it) Miscele di agenti stabilizzanti
DK1066276T3 (da) Fremgangsmåde til syntese af HIV protease inhibitor
DE60007360D1 (de) Amorphe modifikation von torasemid
EE200100017A (et) N-tert-butüülhüdroksüülamiini uued soolad
EP1195163A4 (en) Serine protease inhibitors
NO995822D0 (no) Sulfatsalt av en HIV-proteaseinhibitor som har forbedret oral absorpsjon og biotilgjengelighet
NO994415L (no) HIV proteaseinhibitorer
MA26429A1 (fr) Inhibiteurs de protease

Legal Events

Date Code Title Description
KB4A Valid patent at the end of a year

Effective date: 20051231

KB4A Valid patent at the end of a year

Effective date: 20061231

KB4A Valid patent at the end of a year

Effective date: 20071231

KB4A Valid patent at the end of a year

Effective date: 20081231

KB4A Valid patent at the end of a year

Effective date: 20101231

GB1A Change in the ownership or in the address of the owner
HE1A Change of address